American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO) have released a new, evidence-based clinical practice guideline on molecular marker testing for patients with colorectal carcinoma that identifies opportunities for improving patient outcomes.
This pivotal guideline addresses a wide range of molecular markers appropriate for testing in patients with early and advanced colorectal cancer. This guideline will aid in establishing standard molecular marker testing to help guide targeted therapy decisions, and advance personalized care for colorectal cancer patients.
“The evidence-based recommendations for this guideline focused on molecular biomarkers identified as the most useful in patients with colorectal cancer, in order to select patients who can benefit from enhanced treatment with targeted therapies,” said Antonia R. Sepulveda, MD, PhD, Columbia University, project co-chair on behalf of AMP.
The manuscript, "Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline," was published for early simultaneous online release on February 6, 2017, in The American Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, The Journal of Molecular Diagnostics, and Journal of Clinical Oncology followed by publication in each journal.